Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Kindstar Globalgene Technology Days Payable?
Kindstar Globalgene TechnologyHKSE:09960 +3.09%69 Days Payable is 105.13 as of Dec. 2025, which is 3% below its 10-year median of 108.65. GuruFocus rates HKSE:09960 with a GF Score™ of 69/100 and a GF Value™ of HK$1.06 (Fairly Valued). The stock has 6 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Kindstar Globalgene Technology ranks better than 66.15% on this metric.
The historical rank and industry rank for Kindstar Globalgene Technology's Days Payable or its related term are showing as below:
HKSE:09960'
s Days Payable Range Over the Past 10 Years
Min: 102.58 Med: 108.65 Max: 186.53
Current: 110.98
During the past 8 years, Kindstar Globalgene Technology's highest Days Payable was 186.53. The lowest was 102.58. And the median was 108.65.
HKSE:09960's Days Payable is ranked better than 66.15% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.785
vs HKSE:09960: 110.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:09960 vs TMO, DHR, NTRA: Days Payable Comparison
For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kindstar Globalgene Technology Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's Days Payable distribution charts can be found below:
* The bar in red indicates where Kindstar Globalgene Technology's Days Payable falls into.
Kindstar Globalgene Technology Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kindstar Globalgene Technology (HKSE:09960) has a Days Payable of 105.13 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kindstar Globalgene Technology and its competitors. This is near median its historical median of 108.65. Over the past decade, Kindstar Globalgene Technology's Days Payable has ranged from 102.58 to 186.53. According to the industry distribution chart, Kindstar Globalgene Technology ranks #65 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 33.9%.
Is Kindstar Globalgene Technology's Days Payable too high?
Kindstar Globalgene Technology's current Days Payable of 105.13 is near median its 10-year median of 108.65. Over the past 10 years, this metric has ranged from a low of 102.58 to a high of 186.53. The Medical Diagnostics & Research industry median Days Payable is 65.79. Kindstar Globalgene Technology's value of 105.13 is 59.8% above this industry median. Based on the distribution chart, Kindstar Globalgene Technology ranks #65 out of 192 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Kindstar Globalgene Technology has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kindstar Globalgene Technology's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Kindstar Globalgene Technology ranks #65 out of 192 companies for Days Payable. This puts Kindstar Globalgene Technology in the upper half of its industry. The industry median Days Payable is 65.79. Kindstar Globalgene Technology's value of 105.13 is 59.8% above this benchmark. Historically, Kindstar Globalgene Technology's own Days Payable has ranged from 102.58 to 186.53 over the past decade. While the company's 10-year median is 108.65 vs. the industry median of 65.79, Kindstar Globalgene Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.79, based on 192 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kindstar Globalgene Technology's current Days Payable of 105.13 is 59.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kindstar Globalgene Technology and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kindstar Globalgene Technology's current Days Payable is 105.13, which is near median its own 10-year median of 108.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kindstar Globalgene Technology stock overvalued right now?
Based on GuruFocus' analysis, Kindstar Globalgene Technology (HKSE:09960) is currently considered Fairly Valued. The stock's GF Value™ is HK$1.06, compared to a current price of HK$1.00 — trading 5.7% below its estimated fair value. The current Days Payable is 105.13, which is near median its 10-year median of 108.65 and 59.8% above the Medical Diagnostics & Research industry median of 65.79. Kindstar Globalgene Technology's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Kindstar Globalgene Technology (HKSE:09960), the current Days Payable is 105.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kindstar Globalgene Technology (HKSE:09960) Overvalued in 2026?
Based on GuruFocus' analysis, Kindstar Globalgene Technology stock appears to be undervalued.
The current stock price of HK$1.00 is trading 5.7% below its estimated GF Value™ of HK$1.06.
GuruFocus considers Kindstar Globalgene Technology to be Fairly Valued.
Key valuation signals for HKSE:09960:
Days Payable: 105.13 (near median its 10-year median of 108.65)
GF Value™: HK$1.06 vs. price of HK$1.00 (5.7% below fair value)
Industry Position: 59.8% above the Medical Diagnostics & Research median (#65 of 192)
No single metric tells the full story. See the HKSE:09960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kindstar Globalgene Technology Inc is engaged in the provision of clinical testing services in China. It operates in nine segments: Hematology testing segment includes testing services related to blood diseases; Genetic diseases and rare diseases segment includes testing services for rare diseases; Infectious diseases segment includes testing services from the infection department; Oncology segment includes testing related to oncology diseases; Neurology segment includes testing services related to neurological diseases undertaken by the Group; Maternity-related diseases segment includes testing services related to maternity; Routine testing segment conducts routine tests for the doctors daily diagnoses; CROs & R&D project segment includes research & develop services; & others segment.
69GF Score
Get the complete analysis for HKSE:09960
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09960 has been successfully added to your 
